Contact Us
Drug Search Results
More Filters [+]

Ebselen

Alternative Names: ebselen, spi-1005
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

Sound is developing Ebselen as a treatment for Meniere's Disease, Acute NIHL, and COVID-19. (Sourced from: https://soundpharma.com/pipeline/)

Mechanisms of Action: HDAC1 Inhibitor,HDAC3 Inhibitor,HDAC4 Inhibitor,HDAC5 Inhibitor,HDAC6 Inhibitor,HDAC7 Inhibitor,HDAC8 Inhibitor,HDAC9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sound
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ebselen

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Meniere Disease

Phase 2: COVID-19|Communicable Diseases|Cystic Fibrosis|Hearing Loss|Hearing Loss, Sensorineural|Pulmonary Fibrosis|Tinnitus|Vertigo

Phase 1: Depressive Disorder, Treatment-Resistant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SPI-1005-261

P2

Not yet recruiting

Hearing Loss

2025-12-01

24%
OxIMP

P1

Recruiting

Depressive Disorder, Treatment-Resistant

2024-05-31

SPI-1005-291

P2

Enrolling by invitation

COVID-19|Communicable Diseases

2023-12-31

25%
SPI-1005-292

P2

Enrolling by invitation

Communicable Diseases|COVID-19

2023-12-31

25%

Recent News Events

Date

Type

Title

12/10/2024

News Article

 Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere's Disease with SPI-1005

10/30/2024

News Article

 TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic

07/31/2024

News Article

 Sound Pharma Announces Phase 3 Study Completion of SPI-1005 for the Treatment of Meniere's Disease

05/20/2024

News Article

 Sound Pharmaceuticals' IND Involving Cochlear Implantation Allowed by the FDA

05/07/2024

PubMed

 Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication.

04/30/2024

PubMed

 Exploring Antiviral Drugs on Monolayer Black Phosphorene: Atomistic Theory and Explainable Machine Learning-Assisted Platform.

03/19/2024

PubMed

 Ebselen analogues with dual human neutrophil elastase (HNE) inhibitory and antiradical activity.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions